Robert Lin is Co-Founder and Chief Technology Officer at Taudia, a pioneering diagnostics company developing ultrasensitive blood-based biomarker detection technology for Alzheimer's disease and neurodegenerative diseases.

Robert earned his PhD in Biomedical Engineering from the University of California, Irvine, and built over a decade of product development expertise across the IVD and research-use-only (RUO) spaces.

He led next-generation platform development at Cepheid and drove microfluidics innovation at Combinati before serving as Senior Product Manager at Thermo Fisher Scientific, giving him rare end-to-end commercialization insight.

His drive to improve lives through science and technology inspired him to co-found Taudia, where he now leads the engineering and technical development of the SPLASH and NeuXplore diagnostic platforms.

Taudia's sample-to-answer platform delivers clinically meaningful blood biomarker results in under four hours, enabling researchers, biopharma teams, and clinicians to detect neurodegenerative biomarkers without complex or invasive procedures.